<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-19602" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Clindamycin</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Murphy</surname>
            <given-names>Patrick B.</given-names>
          </name>
          <aff>Desert Regional Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Bistas</surname>
            <given-names>Karlyle G.</given-names>
          </name>
          <aff>Medical University of the Americas</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Preeti</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Le</surname>
            <given-names>Jacqueline K.</given-names>
          </name>
          <aff>Desert Regional Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Patrick Murphy declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Karlyle Bistas declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Preeti Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Jacqueline Le declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>28</day>
          <month>2</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-19602.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">This activity focuses on the comprehensive spectrum of indications and applications for clindamycin, a potent antimicrobial agent widely utilized to manage diverse infections. From septicemia to gynecological infections, lower respiratory infections to skin and skin structure infections, clindamycin effectively addresses many bacterial pathogens. This program systematically explores clindamycin's therapeutic actions, offering healthcare providers a nuanced understanding of its mechanisms, contraindications, potential drug interactions, and associated adverse events. By delving into clindamycin's clinical applications, this&#x000a0;activity equips healthcare professionals with the knowledge to integrate this antimicrobial drug into their&#x000a0;practice to treat various infectious conditions effectively, fostering improved patient outcomes.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify appropriate indications for clindamycin therapy based on the type of infection and susceptibility patterns.</p></list-item><list-item><p>Screen patients for potential contraindications, allergies, and drug interactions before initiating clindamycin therapy.</p></list-item><list-item><p>Apply principles of antimicrobial stewardship when prescribing clindamycin to promote responsible antibiotic use.</p></list-item><list-item><p>Implement strategies&#x000a0;with other healthcare professionals, including pharmacists, infectious disease specialists, and microbiologists, to optimize clindamycin therapy.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=19602&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=19602">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-19602.s2" sec-type="Indications">
        <title>Indications</title>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <p>Clindamycin is FDA-approved to treat septicemia, intra-abdominal infections, lower respiratory infections, gynecological infections, bone and joint infections, and skin and skin structure infections. Clindamycin is also used to treat streptococcal pharyngitis, acne vulgaris, bacterial vaginosis, and&#x000a0;severe pelvic&#x000a0;inflammatory&#x000a0;disease. Although not a first-line treatment, The Infectious Diseases Society of America (IDSA) has published&#x000a0;guidelines for using intravenous (IV) clindamycin for the inpatient treatment of community-acquired pneumonia and aspiration pneumonia.&#x000a0;</p>
        <p>Dentists&#x000a0;will use clindamycin for prophylactic coverage against endocarditis.&#x000a0;Anesthesiologists and surgeons will often administer&#x000a0;clindamycin as prophylaxis in the operating room per The American Society of Health-System Pharmacists (ASHP) and IDSA&#x000a0;guidelines. Gynecologists use clindamycin and gentamycin &#x000b1; ampicillin to cover their patients with endometritis. Clindamycin can also be an alternative to metronidazole for treating <italic toggle="yes">Gardnerella</italic> vaginosis, which presents with a gray, fishy vaginal odor&#x000a0;and clue cells on wet prep.<xref ref-type="bibr" rid="article-19602.r1">[1]</xref><xref ref-type="bibr" rid="article-19602.r2">[2]</xref></p>
        <p>Additionally, clindamycin can treat babesiosis, anthrax, and&#x000a0;malaria. Clindamycin is also commonly used in uncomplicated skin and soft tissue infections. Clindamycin is used in soft tissue infections due to its efficacy against MRSA. Clindamycin is also a choice for outpatient treatment because of its cost, availability, and effectiveness against methicillin-resistant <italic toggle="yes">Staphylococcus aureus</italic>.<xref ref-type="bibr" rid="article-19602.r3">[3]</xref></p>
        <p>
<bold>Off-Label Uses</bold>
</p>
        <p>Clindamycin is indicated as an off-label prescription for use in the treatment of acne. Also,&#x000a0;this drug is used to treat opportunistic infections such as pneumocystis pneumonia and toxoplasmosis in patients with HIV.<xref ref-type="bibr" rid="article-19602.r4">[4]</xref>&#x000a0;Clindamycin is indicated for patients who developed a malarial infection and are resistant to chloroquine.<xref ref-type="bibr" rid="article-19602.r5">[5]</xref>&#x000a0;Clindamycin is used to treat acute osteomyelitis caused by S<italic toggle="yes">taphylococcus aureus</italic> and as an&#x000a0;adjunct&#x000a0;treatment for chronic bone and joint infections caused by susceptible organisms.<xref ref-type="bibr" rid="article-19602.r6">[6]</xref><xref ref-type="bibr" rid="article-19602.r7">[7]</xref></p>
      </sec>
      <sec id="article-19602.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Clindamycin prevents peptide bond formation, inhibiting protein synthesis by reversibly binding to 50S ribosomal subunits. Depending on the organism, infection site, and drug concentration, clindamycin may be a bacteriostatic or bactericidal antibiotic.<xref ref-type="bibr" rid="article-19602.r8">[8]</xref>&#x000a0;Mutation of specific bases at 23s rRNA is responsible for developing resistance in clindamycin. Other antibiotics, such as macrolides, lincosamides, and streptogramin B, whose binding sites in bacteria are the same as that of clindamycin,&#x000a0;so clindamycin may show a cross-resistance pattern with these antibiotics.</p>
        <p>Clindamycin is active in treating infection caused by gram-positive organisms such as <italic toggle="yes">Staphylococcus aureus&#x000a0;</italic>(methicillin-susceptible strains), <italic toggle="yes">Streptococcus pneumoniae&#x000a0;</italic>(penicillin-susceptible strains), and <italic toggle="yes">Streptococcus pyogenes.</italic><xref ref-type="bibr" rid="article-19602.r9">[9]</xref><xref ref-type="bibr" rid="article-19602.r10">[10]</xref>&#x000a0;Clindamycin is also proven to be effective in infection caused by anaerobic bacteria such as <italic toggle="yes">Clostridium perfringens</italic>, <italic toggle="yes">Fusobacterium necrophorum</italic>, <italic toggle="yes">Fusobacterium nucleatum</italic>, <italic toggle="yes">Peptostreptococcus anaerobius,</italic> and <italic toggle="yes">Prevotella melaninogenica.</italic><xref ref-type="bibr" rid="article-19602.r11">[11]</xref><xref ref-type="bibr" rid="article-19602.r12">[12]</xref><xref ref-type="bibr" rid="article-19602.r13">[13]</xref><xref ref-type="bibr" rid="article-19602.r14">[14]</xref>&#x000a0;</p>
        <p>Certain strains of macrolide-resistant bacteria result in clindamycin resistance. The D-zone test should evaluate the resistance pattern of beta-hemolytic streptococci and staphylococci.<xref ref-type="bibr" rid="article-19602.r15">[15]</xref><xref ref-type="bibr" rid="article-19602.r16">[16]</xref></p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption: </bold>Absorption cannot occur until clindamycin palmitate hydrolyzes in the gastrointestinal (GI) tract. Absorption of clindamycin through oral dosage form is achieved rapidly with excellent absorption (90%).&#x000a0;The therapeutic blood concentration of clindamycin is typically&#x000a0;attained within 45 minutes after oral administration. When administered orally, the&#x000a0;peak concentration is achieved in about 60 minutes.</p>
        <p>When given intramuscularly (IM), the drug&#x000a0;reaches peak concentrations in 1 to 3 hours. Peak serum concentrations of clindamycin are attained upon completing a short-term intravenous infusion. Oral clindamycin, administered at a daily dose of 2 grams for 14 days, shows no evidence of drug accumulation. Food does not affect the bioavailability of clindamycin. Clindamycin is generally well tolerated. However, GI&#x000a0;adverse effects may occur at higher doses.</p>
        <p><bold>Distribution: </bold>The phosphate salt of clindamycin available as an injection dosage form is a prodrug, and its active metabolite is clindamycin after the first pass metabolite. Clindamycin intravenous infusion attains the maximum concentration within a short duration of time. Intramuscular administration of clindamycin results in a peak plasma concentration of approximately 3 hours for adult patients and around 1 hour for the pediatric population. The blood concentration is directly proportional to the dose of clindamycin.</p>
        <p>Clindamycin is distributed widely throughout&#x000a0;the whole body, including bones. Clindamycin cannot efficiently penetrate meninges very well and is, therefore, not an antibiotic of choice for infections of the cerebrospinal fluid (CSF). The topical application of clindamycin in the formulation of a gel, lotion, or cream achieves an equivalent dose to that of clindamycin in an isopropyl alcohol and water solution. In patients with obesity, ranging from 2 to 20 years of age, the clearance and volume of distribution of clindamycin have been observed to remain unchanged and comparable to individuals without obesity.<xref ref-type="bibr" rid="article-19602.r17">[17]</xref></p>
        <p><bold>Metabolism: </bold>Hepatic cytochrome P450 isoenzyme CYP3A4 is responsible for the metabolism of clindamycin to form clindamycin sulfoxide and a minor metabolite, N-desmethyl clindamycin. Along with CYP3A4 as a major enzyme, CYP3A5 is also involved in the metabolism of clindamycin.<xref ref-type="bibr" rid="article-19602.r18">[18]</xref></p>
        <p><bold>Excretion: </bold>The elimination half-life of clindamycin is around 3 hours in the adult population and approximately 2.5 hours in pediatric patients.&#x000a0;The elimination half-life is increased in renal or hepatic impairment. Most clindamycin is excreted as active and inactive metabolites in urine (major) and feces (minor).<xref ref-type="bibr" rid="article-19602.r19">[19]</xref></p>
      </sec>
      <sec id="article-19602.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Forms</bold>
</p>
        <p>Clindamycin can be administered by multiple routes and is available as a topical gel,&#x000a0;foam, lotion, or solution for treating acne vulgaris. A thin film needs to be applied twice a day.<xref ref-type="bibr" rid="article-19602.r20">[20]</xref>&#x000a0;Clindamycin&#x000a0;is also available as a cream or suppository for intravaginal administration to treat bacterial vaginosis.<xref ref-type="bibr" rid="article-19602.r21">[21]</xref></p>
        <p>
<bold>Available Strengths</bold>
</p>
        <p>Systemic infections can be treated orally with a capsule (75 mg, 150 mg, 300 mg) or in solution (75 mg/5 mL). To minimize esophageal ulceration, administer orally with a full glass of water.<xref ref-type="bibr" rid="article-19602.r22">[22]</xref> The absorption of clindamycin granules is not adversely affected by co-administration with food.</p>
        <p>Clindamycin&#x000a0;is also available as an intramuscular injection (9 g/60 mL, 300 mg/2 mL, 600 mg/4 mL, 900 mg/6 mL). Intravenous formulations are available as follows: clindamycin phosphate (300 mg/2 mL, 600 mg/4 mL, 900 mg/6 mL), and clindamycin phosphate in D5W or NaCl (300 mg/50 mL, 600 mg/50 mL, 900 mg/50 mL). When administered intramuscularly, the sites must require rotation with no dose exceeding 600 mg in a single injection. Clindamycin is administered by intravenous (IV) intermittent infusion over at least 10 to 60 minutes at a maximum rate of 30 mg/min. The final concentration of the IV solution should not exceed 18 mg/mL.</p>
        <p>
<bold>Specific Patient Population</bold>
</p>
        <p><bold>Hepatic Impairment:&#x000a0;</bold>Dosage schedules&#x000a0;do not require changes in the presence of mild or moderate hepatic impairment. Caution is advised in severe hepatic impairment (Child-Pugh C), requiring dose adjustment and monitoring of&#x000a0;liver function tests.<xref ref-type="bibr" rid="article-19602.r23">[23]</xref></p>
        <p><bold>Renal Impairment: </bold>Renal impairment can increase clindamycin's elimination half-life. No dose adjustment of clindamycin is required for mild to moderate renal impairment. Peritoneal and hemodialysis are ineffective in removing clindamycin from the systemic circulation.</p>
        <p><bold>Pregnancy Considerations: </bold>Clindamycin has not shown an increased frequency of congenital abnormalities when systemically administered during the second and third trimesters of pregnancy in clinical trials with pregnant patients. Clindamycin should be used during the first trimester of pregnancy only if deemed necessary due to a lack of clinical studies. No teratogenic effects were observed in reproduction studies with clindamycin in rats and mice. According to the American College of Obstetricians and Gynecologists (ACOG) guidelines for Group B streptococcal (GBS) infection, intravenous penicillin is recommended for intrapartum prophylaxis. However, clindamycin is the suggested alternative if there is a&#x000a0;significant risk of anaphylaxis to penicillin or if the GBS isolate is susceptible to clindamycin.<xref ref-type="bibr" rid="article-19602.r24">[24]</xref></p>
        <p><bold>Breastfeeding Considerations: </bold>Clindamycin can affect the gastrointestinal flora of breastfed infants. Nursing mothers can generally continue breastfeeding if they require oral or intravenous clindamycin, although an alternative drug may be preferred. Infants should be monitored for possible gastrointestinal effects such as diarrhea, candidiasis, or rare cases of colitis.&#x000a0;Vaginal application rarely causes adverse effects in infants. Topical administration of clindamycin for acne is unlikely to cause adverse effects in infants. However, applying clindamycin topically to the breast may increase the risk of diarrhea if ingested by the infant. Only use water-miscible cream, foam, gel, or liquid products on the breast to avoid exposing the infant to high levels of mineral paraffin through licking.<xref ref-type="bibr" rid="article-19602.r25">[25]</xref></p>
        <p><bold>Pediatric Patients:</bold> Pediatric dosing for neonates is 15 to 20 mg/kg/d, over 6 to 8 hours (IM or IV). Infants, children, and adolescents are treated with 8 to 40 mg/kg/d divided over 3 to 4 doses (oral). For IM/IV administration, 20 to 40 mg/kg/d can be given over 3 to 4 divided doses.<xref ref-type="bibr" rid="article-19602.r26">[26]</xref></p>
        <p><bold>Older&#x000a0;Patients:</bold> Limited data from clinical studies on clindamycin does not provide information about potential differences in response between&#x000a0;older and younger patients. Antibiotic-associated colitis and diarrhea are more prevalent in older patients.<xref ref-type="bibr" rid="article-19602.r27">[27]</xref></p>
      </sec>
      <sec id="article-19602.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>The adverse effects of clindamycin vary based on how its mode of administration. The most common&#x000a0;adverse effects experienced with topical use include pruritis, xeroderma, erythema, burning, exfoliation, or oily skin. The most common side effects of intravaginal administration are vaginal candidiasis, pruritis, vulvovaginal disease, and vulvovaginitis. With systemic administration, the primary adverse effects of clindamycin are pseudomembranous colitis, nausea, vomiting, and diarrhea, resulting from clindamycin destroying much of the GI tract&#x02019;s healthy flora. <italic toggle="yes">Clostridium difficile</italic>&#x000a0;rapidly&#x000a0;overgrows in this environment. The A and B toxins produced by <italic toggle="yes">C. difficile</italic>&#x000a0;cause <italic toggle="yes">Clostridium difficile</italic>-associated diarrhea (CDAD). If suspected, a stool antigen test should be in order.</p>
        <p>Severe cases that result from hypertoxic-producing strains occur in an increase in morbidity and mortality, which may require colectomy for definitive treatment. Other adverse effects include thrombophlebitis or metallic taste with IV administration, azotemia, agranulocytosis, anaphylactic shock, abscess formation, induration, or irritation at the IM injection site.&#x000a0;Allergic contact dermatitis due to topical clindamycin has been reported.<xref ref-type="bibr" rid="article-19602.r28">[28]</xref><xref ref-type="bibr" rid="article-19602.r29">[29]</xref></p>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <p><bold>Neuromuscular Blocking Agents:</bold>&#x000a0;Clindamycin has neuromuscular blocking actions; monitoring and caution are required when co-administering it with other neuromuscular blocking drugs like atracurium, cisatracurium, and rocuronium.<xref ref-type="bibr" rid="article-19602.r30">[30]</xref></p>
        <p><bold>CYP3A4 Inhibitors/Inducers:</bold> Clindamycin is primarily metabolized by the enzymes CYP3A4, with a minor contribution from CYP3A5. When drugs that inhibit CYP3A4 and CYP3A5 are used, the levels of clindamycin in the bloodstream can increase, while medications that induce these enzymes can lower their levels. Drugs such as rifampicin, known to induce CYP3A4, may result in increased metabolism and reduced efficacy of clindamycin.<xref ref-type="bibr" rid="article-19602.r31">[31]</xref></p>
      </sec>
      <sec id="article-19602.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Clindamycin is contraindicated in patients with a history of pseudomembranous colitis&#x000a0;and ulcerative colitis. Care is also necessary for antibiotic use as bacterial and fungal superinfections may occur. Clindamycin is also contraindicated in patients with hypersensitivity to clindamycin, lincomycin, or any of its components. Special care must also be taken in patients with atopic dermatitis as colonization is more prevalent in this patient population. The pathogenicity of skin infections is higher in this population; this is important for future infections as antibiotic resistance is problematic.<xref ref-type="bibr" rid="article-19602.r32">[32]</xref></p>
        <p><bold>Box Warnings</bold>&#x000a0;</p>
        <p>Clindamycin has a similar potency to develop&#x000a0;<italic toggle="yes">Clostridium difficile-associated</italic>&#x000a0;diarrhea, such as other antibacterial agents, and the implication of this may be from mild diarrhea and life-threatening colitis. If the patient develops symptoms of <italic toggle="yes">Clostridium difficile</italic>-associated diarrhea (CDAD), then discontinuation of clindamycin is recommended, and a&#x000a0;prompt evaluation and treatment of colitis should be instituted.<xref ref-type="bibr" rid="article-19602.r33">[33]</xref></p>
        <p>
<bold>Warnings and Precautions&#x000a0;</bold>
</p>
        <p>When clindamycin is prescribed in&#x000a0;older individuals, caution and monitoring are necessary as this population&#x000a0;is vulnerable to clindamycin-associated CDAD. Clindamycin should be used cautiously in patients with gastrointestinal disorders and atopic diseases. When&#x000a0;clindamycin is prescribed in patients with liver&#x000a0;disorders, periodic monitoring of liver function is advised due to concern for hepatotoxicity.<xref ref-type="bibr" rid="article-19602.r23">[23]</xref>&#x000a0;</p>
        <p>Use&#x000a0;clindamycin capsules cautiously for individuals at risk of developing allergic reactions, such as bronchial asthma, due to the presence of the excipient tartrazine, which can trigger allergic reactions.<xref ref-type="bibr" rid="article-19602.r34">[34]</xref> When the therapeutic regimen is designed with clindamycin, differential diagnosis with confirmed bacterial infection and susceptibility should be ensured to avoid the development of bacterial resistance.<xref ref-type="bibr" rid="article-19602.r35">[35]</xref></p>
      </sec>
      <sec id="article-19602.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Changes in bowel frequency, colitis, and resolution of symptoms should be monitored.<xref ref-type="bibr" rid="article-19602.r32">[32]</xref>&#x000a0;Liver function tests should be monitored periodically in patients with&#x000a0;severe&#x000a0;liver disease. Complete blood cell count (CBC), liver, and renal function should be monitored in prolonged therapy. Adequately managing fluid and electrolyte replacement in this patient population is vital.&#x000a0;Monitoring is required in patients as&#x000a0;CDAD has been reported to occur even&#x000a0;after&#x000a0;2 months after the administration of clindamycin.<xref ref-type="bibr" rid="article-19602.r36">[36]</xref></p>
      </sec>
      <sec id="article-19602.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>The most common adverse effects due to clindamycin toxicity are gastrointestinal or allergic. There is no antidote for clindamycin toxicity, and the adverse effects will resolve with dose adjustment or discontinuation of the antibiotic. Treatment is supportive. The recommendation is to measure serum electrolytes in patients with vomiting and diarrhea. Vital signs need to be monitored along with CBC with differential, platelets, LFTs, and renal function in symptomatic patients.&#x000a0;The clinical team must also&#x000a0;obtain an EKG and maintain continuous cardiac monitoring as cardiac arrhythmias, although rare, may occur. Evaluation for <italic toggle="yes">Clostridium difficile</italic> toxin will be needed when colitis is suspected.</p>
        <p>Clinicians need to&#x000a0;watch for severe allergic reactions like DRESS or Stevens-Johnson syndrome. Immediately discontinuing&#x000a0;the antibiotic and supportive management, including IV fluids, oxygen therapy, diphenhydramine, and corticosteroids, are crucial in these situations. In cases of severe hypotension, administering fluid boluses and starting vasopressors may be necessary. Airway management is likely unnecessary, but severe anaphylactic reactions require airway management with endotracheal intubation. Rarely, clindamycin toxicity will lead to cardiac arrhythmias and cardiac arrest, in which case advanced cardiovascular life support will be required.<xref ref-type="bibr" rid="article-19602.r37">[37]</xref></p>
      </sec>
      <sec id="article-19602.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Clindamycin is a widely prescribed drug by many healthcare professionals, including&#x000a0;family practitioners,&#x000a0;internists, infectious disease consultants, emergency department physicians, and advanced practice practitioners. All healthcare workers who prescribe this agent should monitor the patient for changes in bowel frequency, colitis, and resolution of symptoms. Clindamycin&#x000a0;is known to&#x000a0;cause&#x000a0;<italic toggle="yes">Clostridium</italic>&#x000a0;colitis, which extends hospital stays and increases healthcare costs.</p>
        <p>If diarrhea develops, adequately managing fluid and electrolyte replacement is essential in these&#x000a0;patients. Healthcare workers should limit the duration of clindamycin therapy and abstain from empirically prescribing this agent. The joint guidelines by&#x000a0;SHEA/IDSA/APIC suggest that clindamycin and&#x000a0;another antibiotic play a significant role in the development of CDAD<italic toggle="yes">.&#x000a0;</italic>Therefore,&#x000a0;clinicians must prioritize antimicrobial stewardship practices to&#x000a0;decrease the risk of CDAD.<xref ref-type="bibr" rid="article-19602.r38">[38]</xref></p>
        <p>Management of clindamycin therapy will benefit from the efforts of an interprofessional healthcare team that includes the prescribing/ordering physicians and advance practice practitioners, specialists, nursing staff, and pharmacists, all coordinating activity and engaging in open communication about the case and monitoring of the drug to optimize patient outcomes.</p>
      </sec>
      <sec id="article-19602.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=19602&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=19602">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/19602/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=19602">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-19602.s11">
        <title>References</title>
        <ref id="article-19602.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Al Khaja</surname>
                <given-names>KAJ</given-names>
              </name>
              <name>
                <surname>Sequeira</surname>
                <given-names>RP</given-names>
              </name>
            </person-group>
            <article-title>Drug treatment and prevention of malaria in pregnancy: a critical review of the guidelines.</article-title>
            <source>Malar J</source>
            <year>2021</year>
            <month>Jan</month>
            <day>23</day>
            <volume>20</volume>
            <issue>1</issue>
            <fpage>62</fpage>
            <pub-id pub-id-type="pmid">33485330</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19602.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mohammed</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Javed</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Althwanay</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ahsan</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Oliveri</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Goud</surname>
                <given-names>HK</given-names>
              </name>
              <name>
                <surname>Mehkari</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Rutkofsky</surname>
                <given-names>IH</given-names>
              </name>
            </person-group>
            <article-title>Live Bacteria Supplementation as Probiotic for Managing Fishy, Odorous Vaginal Discharge Disease of Bacterial Vaginosis: An Alternative Treatment Option?</article-title>
            <source>Cureus</source>
            <year>2020</year>
            <month>Dec</month>
            <day>29</day>
            <volume>12</volume>
            <issue>12</issue>
            <fpage>e12362</fpage>
            <pub-id pub-id-type="pmid">33527045</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19602.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nagarkoti</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Prajapati</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>AN</given-names>
              </name>
              <name>
                <surname>Gyawali</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Manandhar</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Distribution of Macrolide-Lincosamide-Streptogramin B Antibiotics Resistance Genes in Clinical Isolates of Staphylococci.</article-title>
            <source>J Nepal Health Res Counc</source>
            <year>2021</year>
            <month>Jan</month>
            <day>21</day>
            <volume>18</volume>
            <issue>4</issue>
            <fpage>734</fpage>
            <page-range>734-740</page-range>
            <pub-id pub-id-type="pmid">33510520</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19602.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jorge</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Coelho</surname>
                <given-names>IN</given-names>
              </name>
              <name>
                <surname>Silva-Cunha</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fernandes Cunha</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Scott</surname>
                <given-names>IU</given-names>
              </name>
              <name>
                <surname>Fialho</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Furtado</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Use of a slow-release intravitreal clindamycin implant for the management of ocular toxoplasmosis.</article-title>
            <source>Am J Ophthalmol Case Rep</source>
            <year>2021</year>
            <month>Jun</month>
            <volume>22</volume>
            <fpage>101093</fpage>
            <pub-id pub-id-type="pmid">33981913</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19602.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Daily</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Minuti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis, Treatment, and Prevention of Malaria in the US: A Review.</article-title>
            <source>JAMA</source>
            <year>2022</year>
            <month>Aug</month>
            <day>02</day>
            <volume>328</volume>
            <issue>5</issue>
            <fpage>460</fpage>
            <page-range>460-471</page-range>
            <pub-id pub-id-type="pmid">35916842</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19602.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Congedi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Minotti</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Giaquinto</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Da Dalt</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Don&#x000e0;</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Acute infectious osteomyelitis in children: new treatment strategies for an old enemy.</article-title>
            <source>World J Pediatr</source>
            <year>2020</year>
            <month>Oct</month>
            <volume>16</volume>
            <issue>5</issue>
            <fpage>446</fpage>
            <page-range>446-455</page-range>
            <pub-id pub-id-type="pmid">32394145</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19602.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Colston</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Atkins</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Bone and joint infection.</article-title>
            <source>Clin Med (Lond)</source>
            <year>2018</year>
            <month>Mar</month>
            <volume>18</volume>
            <issue>2</issue>
            <fpage>150</fpage>
            <page-range>150-154</page-range>
            <pub-id pub-id-type="pmid">29626020</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19602.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sp&#x000ed;&#x0017e;ek</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>&#x00158;ezanka</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Lincosamides: Chemical structure, biosynthesis, mechanism of action, resistance, and applications.</article-title>
            <source>Biochem Pharmacol</source>
            <year>2017</year>
            <month>Jun</month>
            <day>01</day>
            <volume>133</volume>
            <fpage>20</fpage>
            <page-range>20-28</page-range>
            <pub-id pub-id-type="pmid">27940264</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19602.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gudiol</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cuervo</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Shaw</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Pujol</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Carratal&#x000e0;</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Pharmacotherapeutic options for treating Staphylococcus aureus bacteremia.</article-title>
            <source>Expert Opin Pharmacother</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>18</volume>
            <issue>18</issue>
            <fpage>1947</fpage>
            <page-range>1947-1963</page-range>
            <pub-id pub-id-type="pmid">29115883</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19602.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Carapetis</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Jacoby</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Carville</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ang</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Curtis</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Andrews</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Effectiveness of clindamycin and intravenous immunoglobulin, and risk of disease in contacts, in invasive group a streptococcal infections.</article-title>
            <source>Clin Infect Dis</source>
            <year>2014</year>
            <month>Aug</month>
            <day>01</day>
            <volume>59</volume>
            <issue>3</issue>
            <fpage>358</fpage>
            <page-range>358-65</page-range>
            <pub-id pub-id-type="pmid">24785239</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19602.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brook</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Spectrum and treatment of anaerobic infections.</article-title>
            <source>J Infect Chemother</source>
            <year>2016</year>
            <month>Jan</month>
            <volume>22</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-13</page-range>
            <pub-id pub-id-type="pmid">26620376</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19602.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Park</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>DY</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>YM</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Kang</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Moon</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Chong</surname>
                <given-names>YP</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>SO</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>YS</given-names>
              </name>
              <name>
                <surname>Woo</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Ryu</surname>
                <given-names>BH</given-names>
              </name>
              <name>
                <surname>Bae</surname>
                <given-names>IG</given-names>
              </name>
              <name>
                <surname>Cho</surname>
                <given-names>OH</given-names>
              </name>
            </person-group>
            <article-title>Selection of an appropriate empiric antibiotic regimen in hematogenous vertebral osteomyelitis.</article-title>
            <source>PLoS One</source>
            <year>2019</year>
            <volume>14</volume>
            <issue>2</issue>
            <fpage>e0211888</fpage>
            <pub-id pub-id-type="pmid">30735536</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19602.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Struzycka</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Mazinska</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Bachanek</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Boltacz-Rzepkowska</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Drozdzik</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kaczmarek</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Kochanska</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Mielczarek</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pytko-Polonczyk</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Surdacka</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tanasiewicz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Waszkiel</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hryniewicz</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Knowledge of antibiotics and antimicrobial resistance amongst final year dental students of Polish medical schools-A cross-sectional study.</article-title>
            <source>Eur J Dent Educ</source>
            <year>2019</year>
            <month>Aug</month>
            <volume>23</volume>
            <issue>3</issue>
            <fpage>295</fpage>
            <page-range>295-303</page-range>
            <pub-id pub-id-type="pmid">30729642</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19602.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ma</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Vaginal microbiota transplantation for the treatment of bacterial vaginosis: a conceptual analysis.</article-title>
            <source>FEMS Microbiol Lett</source>
            <year>2019</year>
            <month>Feb</month>
            <day>01</day>
            <volume>366</volume>
            <issue>4</issue>
            <pub-id pub-id-type="pmid">30715301</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19602.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>He&#x000df;</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gallert</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Resistance behaviour of inducible clindamycin-resistant staphylococci from clinical samples and aquatic environments.</article-title>
            <source>J Med Microbiol</source>
            <year>2014</year>
            <month>Nov</month>
            <volume>63</volume>
            <issue>Pt 11</issue>
            <fpage>1446</fpage>
            <page-range>1446-1453</page-range>
            <pub-id pub-id-type="pmid">25106860</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19602.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marchand-Austin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rawte</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Toye</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Jamieson</surname>
                <given-names>FB</given-names>
              </name>
              <name>
                <surname>Farrell</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>SN</given-names>
              </name>
            </person-group>
            <article-title>Antimicrobial susceptibility of clinical isolates of anaerobic bacteria in Ontario, 2010-2011.</article-title>
            <source>Anaerobe</source>
            <year>2014</year>
            <month>Aug</month>
            <volume>28</volume>
            <fpage>120</fpage>
            <page-range>120-5</page-range>
            <pub-id pub-id-type="pmid">24923267</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19602.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Smith</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Gonzalez</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Goldman</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Yogev</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sullivan</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Reed</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Anand</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Martz</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Berezny</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Benjamin</surname>
                <given-names>DK</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>PB</given-names>
              </name>
              <name>
                <surname>Cohen-Wolkowiez</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Watt</surname>
                <given-names>K</given-names>
              </name>
              <collab>Best Pharmaceuticals for Children Act&#x02014;Pediatric Trials Network Steering Committee</collab>
            </person-group>
            <article-title>Pharmacokinetics of Clindamycin in Obese and Nonobese Children.</article-title>
            <source>Antimicrob Agents Chemother</source>
            <year>2017</year>
            <month>Apr</month>
            <volume>61</volume>
            <issue>4</issue>
            <pub-id pub-id-type="pmid">28137820</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19602.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Armengol &#x000c1;lvarez</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Van de Sijpe</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Desmet</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Metsemakers</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Spriet</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Allegaert</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Rozenski</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Ways to Improve Insights into Clindamycin Pharmacology and Pharmacokinetics Tailored to Practice.</article-title>
            <source>Antibiotics (Basel)</source>
            <year>2022</year>
            <month>May</month>
            <day>21</day>
            <volume>11</volume>
            <issue>5</issue>
            <pub-id pub-id-type="pmid">35625345</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19602.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bookstaver</surname>
                <given-names>PB</given-names>
              </name>
              <name>
                <surname>Bland</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Griffin</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Stover</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Eiland</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>McLaughlin</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>A Review of Antibiotic Use in Pregnancy.</article-title>
            <source>Pharmacotherapy</source>
            <year>2015</year>
            <month>Nov</month>
            <volume>35</volume>
            <issue>11</issue>
            <fpage>1052</fpage>
            <page-range>1052-62</page-range>
            <pub-id pub-id-type="pmid">26598097</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19602.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zaenglein</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Pathy</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Schlosser</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Alikhan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Baldwin</surname>
                <given-names>HE</given-names>
              </name>
              <name>
                <surname>Berson</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Bowe</surname>
                <given-names>WP</given-names>
              </name>
              <name>
                <surname>Graber</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Harper</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Kang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Keri</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Leyden</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Reynolds</surname>
                <given-names>RV</given-names>
              </name>
              <name>
                <surname>Silverberg</surname>
                <given-names>NB</given-names>
              </name>
              <name>
                <surname>Stein Gold</surname>
                <given-names>LF</given-names>
              </name>
              <name>
                <surname>Tollefson</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Weiss</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Dolan</surname>
                <given-names>NC</given-names>
              </name>
              <name>
                <surname>Sagan</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Stern</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Boyer</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Bhushan</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Guidelines of care for the management of acne vulgaris.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2016</year>
            <month>May</month>
            <volume>74</volume>
            <issue>5</issue>
            <fpage>945</fpage>
            <page-range>945-73.e33</page-range>
            <pub-id pub-id-type="pmid">26897386</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19602.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van Schalkwyk</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Yudin</surname>
                <given-names>MH</given-names>
              </name>
              <collab>INFECTIOUS DISEASE COMMITTEE</collab>
            </person-group>
            <article-title>Vulvovaginitis: screening for and management of trichomoniasis, vulvovaginal candidiasis, and bacterial vaginosis.</article-title>
            <source>J Obstet Gynaecol Can</source>
            <year>2015</year>
            <month>Mar</month>
            <volume>37</volume>
            <issue>3</issue>
            <fpage>266</fpage>
            <page-range>266-274</page-range>
            <pub-id pub-id-type="pmid">26001874</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19602.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rutt</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>CE</given-names>
              </name>
            </person-group>
            <article-title>Reaction to Clindamycin Causing Laryngitis and Esophagitis.</article-title>
            <source>Ear Nose Throat J</source>
            <year>2021</year>
            <month>Jul</month>
            <volume>100</volume>
            <issue>6</issue>
            <fpage>437</fpage>
            <page-range>437-438</page-range>
            <pub-id pub-id-type="pmid">31569974</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19602.r23">
          <label>23</label>
          <element-citation publication-type="book">
            <chapter-title>Clindamycin</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2019</year>
            <month>12</month>
            <day>16</day>
            <pub-id pub-id-type="pmid">31643615</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19602.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <article-title>Prevention of Group B Streptococcal Early-Onset Disease in Newborns: ACOG Committee Opinion Summary, Number 782.</article-title>
            <source>Obstet Gynecol</source>
            <year>2019</year>
            <month>Jul</month>
            <volume>134</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <pub-id pub-id-type="pmid">31241596</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19602.r25">
          <label>25</label>
          <element-citation publication-type="book">
            <chapter-title>Clindamycin</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2021</year>
            <month>2</month>
            <day>15</day>
            <pub-id pub-id-type="pmid">30000267</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19602.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Greenberg</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Maharaj</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cohen-Wolkowiez</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tomashek</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Osborn</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Clark</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Walter</surname>
                <given-names>EB</given-names>
              </name>
            </person-group>
            <article-title>A Pharmacoepidemiologic Study of the Safety and Effectiveness of Clindamycin in Infants.</article-title>
            <source>Pediatr Infect Dis J</source>
            <year>2020</year>
            <month>Mar</month>
            <volume>39</volume>
            <issue>3</issue>
            <fpage>204</fpage>
            <page-range>204-210</page-range>
            <pub-id pub-id-type="pmid">31725114</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19602.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Soraci</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Cherubini</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Paoletti</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Filippelli</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Luciani</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Lagan&#x000e0;</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gambuzza</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Filicetti</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Corsonello</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lattanzio</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Safety and Tolerability of Antimicrobial Agents in the Older Patient.</article-title>
            <source>Drugs Aging</source>
            <year>2023</year>
            <month>Jun</month>
            <volume>40</volume>
            <issue>6</issue>
            <fpage>499</fpage>
            <page-range>499-526</page-range>
            <pub-id pub-id-type="pmid">36976501</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19602.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mose</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Adwa</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Svedman</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Allergic Contact Dermatitis to Topical Clindamycin in a Patient with Hidradenitis Suppurativa.</article-title>
            <source>Acta Derm Venereol</source>
            <year>2022</year>
            <month>Sep</month>
            <day>28</day>
            <volume>102</volume>
            <fpage>adv00779</fpage>
            <pub-id pub-id-type="pmid">35971837</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19602.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Savaris</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>Fuhrich</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Duarte</surname>
                <given-names>RV</given-names>
              </name>
              <name>
                <surname>Franik</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ross</surname>
                <given-names>JDC</given-names>
              </name>
            </person-group>
            <article-title>Antibiotic therapy for pelvic inflammatory disease: an abridged version of a Cochrane systematic review and meta-analysis of randomised controlled trials.</article-title>
            <source>Sex Transm Infect</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>95</volume>
            <issue>1</issue>
            <fpage>21</fpage>
            <page-range>21-27</page-range>
            <pub-id pub-id-type="pmid">30341232</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19602.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>SI</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Oh</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Bae</surname>
                <given-names>JY</given-names>
              </name>
            </person-group>
            <article-title>The synergistic effect of gentamicin and clindamycin on rocuronium-induced neuromuscular blockade.</article-title>
            <source>Korean J Anesthesiol</source>
            <year>2013</year>
            <month>Feb</month>
            <volume>64</volume>
            <issue>2</issue>
            <fpage>143</fpage>
            <page-range>143-51</page-range>
            <pub-id pub-id-type="pmid">23459675</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19602.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zeller</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Magreault</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Heym</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Salmon</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kitzis</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Billaud</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Marmor</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jannot</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Salomon</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Jullien</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Influence of the clindamycin administration route on the magnitude of clindamycin-rifampicin interaction: a prospective pharmacokinetic study.</article-title>
            <source>Clin Microbiol Infect</source>
            <year>2021</year>
            <month>Dec</month>
            <volume>27</volume>
            <issue>12</issue>
            <fpage>1857.e1</fpage>
            <page-range>1857.e1-1857.e7</page-range>
            <pub-id pub-id-type="pmid">33915288</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19602.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schr&#x000f6;der</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Gerhard</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Stein</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>[Antibiotic-associated diarrhea].</article-title>
            <source>Z Gastroenterol</source>
            <year>2006</year>
            <month>Feb</month>
            <volume>44</volume>
            <issue>2</issue>
            <fpage>193</fpage>
            <page-range>193-204</page-range>
            <pub-id pub-id-type="pmid">16456762</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19602.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vardakas</surname>
                <given-names>KZ</given-names>
              </name>
              <name>
                <surname>Trigkidis</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Boukouvala</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Falagas</surname>
                <given-names>ME</given-names>
              </name>
            </person-group>
            <article-title>Clostridium difficile infection following systemic antibiotic administration in randomised controlled trials: a systematic review and meta-analysis.</article-title>
            <source>Int J Antimicrob Agents</source>
            <year>2016</year>
            <month>Jul</month>
            <volume>48</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-10</page-range>
            <pub-id pub-id-type="pmid">27216385</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19602.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Andreozzi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Giannetti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cipriani</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Caffarelli</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mastrorilli</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ricci</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Hypersensitivity reactions to food and drug additives: problem or myth?</article-title>
            <source>Acta Biomed</source>
            <year>2019</year>
            <month>Jan</month>
            <day>29</day>
            <volume>90</volume>
            <issue>3-S</issue>
            <fpage>80</fpage>
            <page-range>80-90</page-range>
            <pub-id pub-id-type="pmid">30830065</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19602.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lupinacci</surname>
                <given-names>FS</given-names>
              </name>
              <name>
                <surname>Bussius</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Acquesta</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Fam</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Rossi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Navarini</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mimica</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>High prevalence of clindamycin resistance in <italic>Staphylococcus aureus</italic> blood culture isolates in S&#x000e3;o Paulo, Brazil.</article-title>
            <source>J Lab Physicians</source>
            <year>2017</year>
            <season>Oct-Dec</season>
            <volume>9</volume>
            <issue>4</issue>
            <fpage>314</fpage>
            <page-range>314-316</page-range>
            <pub-id pub-id-type="pmid">28966497</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19602.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Farooq</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Urrunaga</surname>
                <given-names>NH</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>von Rosenvinge</surname>
                <given-names>EC</given-names>
              </name>
            </person-group>
            <article-title>Pseudomembranous colitis.</article-title>
            <source>Dis Mon</source>
            <year>2015</year>
            <month>May</month>
            <volume>61</volume>
            <issue>5</issue>
            <fpage>181</fpage>
            <page-range>181-206</page-range>
            <pub-id pub-id-type="pmid">25769243</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19602.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Paradis</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Marois</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Paradis</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Graham</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>B&#x000e9;gin</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Des Roches</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Anaphylaxis to clindamycin following cutaneous exposure.</article-title>
            <source>Allergy Asthma Clin Immunol</source>
            <year>2020</year>
            <volume>16</volume>
            <fpage>51</fpage>
            <pub-id pub-id-type="pmid">32577121</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19602.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kociolek</surname>
                <given-names>LK</given-names>
              </name>
              <name>
                <surname>Gerding</surname>
                <given-names>DN</given-names>
              </name>
              <name>
                <surname>Carrico</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Carling</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Donskey</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Dumyati</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kuhar</surname>
                <given-names>DT</given-names>
              </name>
              <name>
                <surname>Loo</surname>
                <given-names>VG</given-names>
              </name>
              <name>
                <surname>Maragakis</surname>
                <given-names>LL</given-names>
              </name>
              <name>
                <surname>Pogorzelska-Maziarz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sandora</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Weber</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Yokoe</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Dubberke</surname>
                <given-names>ER</given-names>
              </name>
            </person-group>
            <article-title>Strategies to prevent <italic>Clostridioides difficile</italic> infections in acute-care hospitals: 2022 Update.</article-title>
            <source>Infect Control Hosp Epidemiol</source>
            <year>2023</year>
            <month>Apr</month>
            <volume>44</volume>
            <issue>4</issue>
            <fpage>527</fpage>
            <page-range>527-549</page-range>
            <pub-id pub-id-type="pmid">37042243</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
